-
Announcement of the National Medical Products Administration on the addition of children's drug information to the instructions for haloperidol tablets and other varieties (No. 75 of 2021)
Time of Update: 2021-11-14
Recommendations for revisions to drug inserts of fluoxetine oral preparations National Food and Drug Administration May 28, 2021 Announcement No.
-
The release of heavy documents, the Internet medical industry may welcome a major reshuffle
Time of Update: 2021-11-14
The proposal of the "Draft of Opinions" has just raised the barriers to entry for the industry, which will benefit the development of Internet diagnosis and treatment platforms that provide technical services, and will also bring more challenges to platforms that focus on medical e-commerce .
-
A number of major medical provinces officially began to implement the standard for traditional Chinese medicine formula particles
Time of Update: 2021-11-14
For example, since November 1, the Shaanxi Provincial Food and Drug Administration issued the "Shaanxi Provincial Traditional Chinese Medicine Formula Granule Standard" which has been formally implemented .
-
Traditional Chinese medicine is ushering in a broad space for development, and the status of decocting machine is becoming more and more prominent
Time of Update: 2021-11-14
Therefore, in terms of automation and information technology improvement of the decocting machine, the industry still needs to make continuous efforts to better contribute to the sustainable development of traditional Chinese medicine .
-
The R&D strength of domestic pharmaceutical companies continues to improve, and the authorized transactions of pharmaceutical companies are becoming more frequent
Time of Update: 2021-11-14
Recently, Shanghai Pharmaceuticals announced that it has reached an exclusive license agreement with HUYABIO, authorizing it to obtain the rights to manufacture, develop and commercialize SPH6162 outside of China .
-
Domestic pharmaceutical anti-monopoly efforts continue to increase, and another API company has been fined
Time of Update: 2021-11-14
In fact, in the pharmaceutical industry, there has always been a phenomenon in the field of APIs that related companies use market monopoly positions to manipulate prices for profiteering, or impose unreasonable trading conditions for unfair competition .
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Propylthiouracil Preparations (No. 103 of 2021)
Time of Update: 2021-11-14
The marketing authorization holders of the above-mentioned drugs shall be in accordance with the "Administrative Measures for Drug Registration" and other relevant regulations, and in accordance with the requirements for the revision of the propylthiouracil preparation instructions (see attachment), before November 22, 2021 Report to the provincial drug supervision and administration department for the record .
-
Tianjing Biotech further strengthens the executive team and announces new chief financial officer and chief strategy officer
Time of Update: 2021-11-14
Shanghai, China and Gaithersburg, USA, November 1, 2021/PRNewswire/ - Tianjing Bio ("Company") (NASDAQ: IMAB) is a company that is moving from the clinical stage to commercialization Biopharmaceutical companies are committed to target biological research of innovative biological drugs, antibody technology, clinical development and product commercialization in China and the United States, and provide new and effective treatment methods for the urgently needed cancer treatment fields around the world .
-
Boehringer Ingelheim announced that the European Medicines Agency has accepted and reviewed the marketing authorization application for spesolimab for the treatment of generalized pustular psoriasis
Time of Update: 2021-11-14
"GPP is a rare and life-threatening neutrophil skin disease characterized by the sudden appearance of sterile, pus-filled blisters and painful sensations all over the body," said Janine, Boehringer Ingelheim Global Head of Spesolimab Lamar said .
[6],[7]About generalized pustular psoriasisGPP is a rare, heterogeneous, and life-threatening neutrophilic skin disease, which is clinically different from plaque psoriasis .
-
AstraZeneca sells two COPD drugs for $270 million
Time of Update: 2021-11-14
Eklira is a long-acting muscarinic antagonist (LAMA), which was approved for marketing in the European Union and the United States in 2012 .
-
To accelerate innovation and upgrading, pharmaceutical companies are constantly introducing new drugs
Time of Update: 2021-11-14
In this context, the industry believes that in the future, more and more pharmaceutical companies will frequently introduce new drugs, enrich their product pipelines through the license in (authorized introduction) model, and enhance their innovation capabilities.
-
21 batches of medicines in Yunnan Province were found to be unqualified, and Chinese herbal medicines accounted for the majority
Time of Update: 2021-11-14
Subsequently, in May of the same year, the State Food and Drug Administration held a video and telephone conference, requesting drug regulatory authorities at all levels to implement territorial regulatory responsibilities in accordance with the "four strictest" requirements, carefully inspect the production and operation units of traditional Chinese medicine decoction pieces and preparations, and resolutely investigate and punish violations of the law.
-
Pfizer's new crown vaccine Comirnaty's revenue in the first three quarters was US$24.3 billion
Time of Update: 2021-11-14
Pfizer therefore raised its full-year revenue forecast to US$81-82 billion .
77 billion in the single quarter of 2021Q3, and sales revenue of US$24.
Pfizer expects that Comirnaty's production capacity will be expanded to 4 billion doses in 2022, and its annual revenue is estimated to be 29 billion US dollars .
-
CDE publicly solicits ICH E14, Q&A and Q3C (R8) guidelines for implementation suggestions
Time of Update: 2021-11-14
On November 2, the CDE official website issued an announcement stating that in order to do a good job in the implementation of the ICH guidelines, the center drafted the ICH "E14 and Questions and Answers: Non-antiarrhythmic drugs cause QT/QTc interval prolongation and potential arrhythmic effects.
-
Entering November, there are new changes in the executives of many pharmaceutical companies
Time of Update: 2021-11-14
Virginia Ellen Maher as the vice president of medical sciences, responsible for the strategy formulation, guidance and supervision of the company’s clinical development projects throughout the cycle, and reported to the company’s Chief Medical Officer (CMO) Patricia Dr.
-
The 31-year-old pharmaceutical company changes ownership!
Time of Update: 2021-11-14
On November 2, Asia-Pacific Pharmaceuticals issued the "Announcement on the Progress of the Judicial Auction of Some Shares of the Controlling Shareholders and Those Acting in Concert".
-
Roche CD20/CD3 bispecific antibody starts clinical trials in China
Time of Update: 2021-11-14
ArticleMedicine GuanlanAccording to the Chinese drug clinical trial registration and information disclosure platform, Roche has initiated a phase 1 clinical study of RO7030816 (mosunetuzumab) in the treatment of patients with relapsed or refractory follicular lymphoma in China .
-
Digital technology + pharmaceutical equipment, or open up a broader market space
Time of Update: 2021-11-14
The industry pointed out that digital technology + pharmaceutical equipment will help companies open up a broader market space .
As more and more pharmaceutical machinery companies gradually transform and upgrade from traditional single equipment suppliers to system integrators and solution providers, they will bring more benefits to customers and create greater value .
-
Yangtze River Class 1 new drug for insomnia enters Phase 3 clinical trial
Time of Update: 2021-11-14
The trial data showed that YZJ-1139 can improve sleep by inhibiting orexin receptors.
This is the first orexin receptor antagonist that has completed Phase 2 clinical trials in China .
-
Corning Jerry appoints Han Jing as chief commercial officer
Time of Update: 2021-11-14
Han Jing has extensive commercialization experience in multinational and local pharmaceutical companies, and has led the team to successfully promote outstanding innovative drugs to The market benefits the majority of patients .